Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

The study, named A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia, is a ...

Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

People with intermediate-risk scores on coronary artery calcium testing who received statins and intensive health coaching ...

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus erythematosus (SLE ...

Japan’s Shionogi (TYO: 4507) yesterday delivered a late-breaking scientific oral presentation at the Conference of ...

Daridorexant, a dual orexin receptor antagonist, is currently approved for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Facephi achieves outstanding results in RIVTD Track 3 Evaluation from Department of Homeland Security (DHS)1 in the USA This evaluation assessed the accuracy and robustness of biometric authentication ...

After hours: March 13 at 7:11:03 PM EDT Loading Chart for SLNO ...